Please assess the completion status of the following clinical trial:

Trial Title: Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* For subjects who participated in F13CD-1725:~* Previous participation (means up to and inclusive Visit 16, (End of Trial)) in F13CD-1725~* For all other subjects:~* Diagnosis of congenital FXIII A-subunit deficiency (confirmed by genotyping at screening visit or documented results from previously performed genotyping)~* Body weight at least 20 kg~Exclusion Criteria:~* Known neutralizing antibodies (inhibitors) towards FXIII~* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency~* Platelet count (thrombocytes) of less than 50 × 109/L. For subjects who participated in F13CD-1725 platelet count from visit 15 in F13CD-1725 must be used for evaluation.~* Females of childbearing potential who are pregnant, breastfeeding or are not using adequate contraceptive methods

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).